Actively Recruiting
Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany
Led by AstraZeneca · Updated on 2026-05-12
438
Participants Needed
6
Research Sites
136 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Heart failure (HF) is a global public health issue that affects more than 63 million people worldwide. The clinical and economic burden of HF on health care systems is substantial. Heart failure with reduced ejection fraction (HFrEF) represents approximately 50% of the HF patient population.The burden of HF is expected to increase substantially as the population ages, and despite improvements in treatment, hospitalisation and mortality rates remain especially high in HFrEF patients. The current guideline recommendation of directed medical therapy for HFrEF combines four drug classes with proven prognostic benefit: Angiotensin receptor-neprilysin inhibitor (ARNI)/angiotensin converting enzyme inhibitors (ACE I)/angiotensin receptor blockers (ARB), betablockers (BB), mineralocorticoid receptor antagonists (MRA), and sodium-glucose co-transporter 2 inhibitors (SGLT2i). The 2023 ESC (European Society of Cardiology) HF guideline update additionally recommends a rapid in-hospital sequencing approach of guideline-directed medical therapy (GDMT) with frequent physician visits during the first 6 weeks post discharge. Studies investigating the implementation of GDMT in a real-world setting have shown that a significant proportion of patients did not receive the recommended drug combination therapy. Delayed initiation of GDMT contributes to the low number of patients receiving guideline concordant HFrEF therapy, which ultimately may affect patient outcomes. One approach to implement the 2023 ESC guideline updates for heart failure treatment regarding early in-hospital initiation and rapid up-titration of GDMT could be to provide specific training on GDMT recommendations. Such a standardised training is offered to the physicians treating HF patients within selected hospitals of the German Helios hospital network (Helios-GDMT-program). Evidence is needed in order to assess whether in-hospital initiation and up-titration of all phenotype concordant classes of GDMT at hospital discharge can be observed after standardised physician training and whether the GDMT-program implementation also translates into real-world routine outpatient care with respect to use of GDMT and clinical outcomes.
CONDITIONS
Official Title
Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at the time of signing the informed consent
- Hospitalized in a participating site with at least 24 hours of inpatient treatment
- Diagnosed with heart failure with reduced ejection fraction (left ventricular EF ≤ 40%) according to current European Society of Cardiology guidelines
- Treated with a maximum of two indicated drug classes (ACE-I/ARNI/ARB, beta blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors) at admission
- Signed and dated informed consent prior to enrollment
- Willing and able to fulfill study requirements listed in the informed consent form
You will not qualify if you...
- Initial hospital presentation with cardiogenic shock or other types of shock
- History of heart transplantation
- Intolerance to one or more GDMT drug classes or significant side effects causing discontinuation of two or more substances within one drug class (except ACE-I/ARB)
- Current or planned participation in another clinical trial
- Investigator decision that participant is unlikely to comply with study procedures
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Research Site
Berlin, Germany, 13125
Actively Recruiting
2
Research Site
Erfurt, Germany, 99089
Actively Recruiting
3
Research Site
Gifhorn, Germany, 38518
Actively Recruiting
4
Research Site
Leipzig, Germany, 04289
Actively Recruiting
5
Research Site
Schwerin, Germany, 19049
Actively Recruiting
6
Research Site
Wuppertal, Germany, 42117
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here